Clinical Trial Update: AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 extension study results for AIN457 regimen in moderate to severe plaque-type psoriasis have been completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis

Drugs mentioned

• AIN457 regimen

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2017-12-05